113 Blood biomarkers during and after treatment [17] Nellessen U, Zingel M, Hecker H, Bahnsen J, Borschke D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy 2010;56:147–52. https://doi.org/10.1159/000313528. [18] D’Errico MP, Rimaldi L, Petruzzelli MF, Placella R, Pili G, Aria M, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left sided breast cancer. Int J Radiat Oncol Biol Phys 2012;82. https://doi. org/10.1016/j.ijrobp.2011.03.058. [19] Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 2014;9:1554–60. https://doi. org/10.1097/JTO.0000000000000306. [20]Skyttä T, Tuohinen S, Boman E, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol 2015;10:1–8. https://doi.org/10.1186/s13014-015-0436-2. [21] Palumbo I, Palumbo B, Fravolini ML, Marcantonini M, Perrucci E, Latini ME, et al. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study. Breast 2015:39–44. https://doi.org/10.1016/j.breast.2015.10.004. [22]Serrano NA, Mikkelsen R, Canada J, Mezzaroma E, Weiss E, Abbate A. Biomarkers of cardiac injury in patients undergoing thoracic radiation therapy. Int J Cardiol 2016;223:507–9. https:// doi.org/10.1016/j.ijcard.2016.08.263. [23]Demissei BG, Freedman G, Feigenberg SJ, Plastaras JP, Maity A, Smith AM, et al. Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer , Lung Cancer , and Lymphoma. Radiat Oncol Biol 2018;103:851–60. https://doi.org/10.1016/j. ijrobp.2018.11.013. [24]Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, et al. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer. Radiother Oncol 2021;156:102– 12. https://doi.org/10.1016/j.radonc.2020.11.032. [25]Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011;79:10–8. https://doi.org/10.1016/j.ijrobp.2009.10.058. [26]Ghobadi G, van der Veen S, Bartelds B, de Boer R a, Dickinson MG, de Jong JR, et al. Physiological interaction of heart and lung in thoracic irradiation. Int J Radiat Oncol Biol Phys 2012;84:e63946. https://doi.org/10.1016/j.ijrobp.2012.07.2362. [27]Ghobadi G, Bartelds B, van der Veen SJ, Dickinson MG, Brandenburg S, Berger RMF, et al. Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax 2012;67:334–41. https://doi.org/10.1136/thoraxjnl-2011-200346. [28]Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol 2019;13. https://doi. org/10.1177/1179546819866445. [29]Banfill K, Abravan A, van Herk M, Sun F, Franks K, McWilliam A, et al. Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer. Front Oncol 2022;12:1–12. https://doi.org/10.3389/fonc.2022.1007577. [30]Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2017;99:128–35. https://doi.org/10.1016/j.ijrobp.2017.05.037. [31] Abravan A, Faivre-Finn C, Kennedy J, McWilliam A, van Herk M. Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. J Thorac Oncol 2020;15:1624– 35. https://doi.org/10.1016/j.jtho.2020.06.008. 7
RkJQdWJsaXNoZXIy MTk4NDMw